Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

ANAB

AnaptysBio Inc

Jan 13 • 04:00PM ET

48.12

-0.90 -1.85 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: XBI VTI IWM IBB VXF IWO SCHA VTWO FFTY DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	6.65%	Shs Outstand	27.58M	Perf Week	9.60%
Market Cap	1.33B	Forward P/E	-	EPS next Y	-4.10	Insider Trans	-7.71%	Shs Float	25.85M	Perf Month	5.12%
Enterprise Value	1.43B	PEG	-	EPS next Q	0.89	Inst Own	109.60%	Short Float	19.89%	Perf Quarter	48.26%
Income	-84.63M	P/S	7.86	EPS this Y	72.35%	Inst Trans	-18.60%	Short Ratio	9.47	Perf Half Y	80.72%
Sales	169.47M	P/B	-	EPS next Y	-189.42%	ROA	-19.99%	Short Interest	5.14M	Perf YTD	-0.73%
Book/sh	-1.07	P/C	5.35	EPS next 5Y	4.12%	ROE	-308.02%	52W High	52.47 -8.28%	Perf Year	238.67%
Cash/sh	8.99	P/FCF	-	EPS past 3/5Y	-34.42% -7.30%	ROIC	-26.87%	52W Low	12.21 294.14%	Perf 3Y	107.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.05% 62.73%	Gross Margin	98.57%	Volatility	7.95% 5.65%	Perf 5Y	94.52%
Dividend TTM	-	EV/Sales	8.44	EPS Y/Y TTM	53.92%	Oper. Margin	-16.92%	ATR (14)	2.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.68	Sales Y/Y TTM	196.42%	Profit Margin	-49.94%	RSI (14)	57.70	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	8.68	EPS Q/Q	145.80%	SMA20	1.97%	Beta	0.36	Target Price	66.00
Payout	-	Debt/Eq	-	Sales Q/Q	154.26%	SMA50	13.30%	Rel Volume	0.61	Prev Close	49.03
Employees	136	LT Debt/Eq	-	Earnings	Nov 04 AMC	SMA200	70.00%	Avg Volume	543.05K	Price	48.12
IPO	Jan 26, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	142.83% 248.19%	Trades		Volume	329,616	Change	-1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$70
Oct-13-25	Initiated	Barclays	Overweight	$78
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$38
Feb-04-25	Initiated	Wolfe Research	Outperform	$25
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28

Show Previous Ratings

Jan-09-26 01:56PM	AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties (Benzinga)
Jan-08-26 06:00PM	Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary (GlobeNewswire)
Jan-06-26 04:15PM	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 12:05PM	This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving (Barchart)
Dec-15-25 07:00AM	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire)
04:15PM	Loading…
Nov-25-25 04:15PM	Anaptys Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-21-25 04:47PM	AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK (Investor's Business Daily) +5.18% +5.91%
06:14AM	GSK, AnaptysBio Sue Each Other Over Cancer Drug License (The Wall Street Journal)
04:00AM	Anaptys Announces $100 Million Stock Repurchase Plan (GlobeNewswire)
03:50AM	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 11:25AM	Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run (Investor's Business Daily) -14.30%
09:00AM	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-04-25 05:50PM	AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Loading…
04:15PM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:15AM	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation (GlobeNewswire)
Oct-28-25 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-13-25 09:15AM	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 (GlobeNewswire)
Sep-29-25 04:05PM	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 (GlobeNewswire) +31.59%
04:05PM	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 (GlobeNewswire)
Aug-27-25 04:15PM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.63%
04:15PM	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Loading…
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)
Jan-31-24 09:15AM	Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-12-24 03:02PM	AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares (GuruFocus.com)
Dec-07-23 09:55AM	Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-14-23 09:35AM	Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround (Zacks) +7.29%
Nov-07-23 04:15PM	Anaptys Named a BioSpace 2024 Best Places to Work Winner (GlobeNewswire) -6.17%
Nov-04-23 05:41AM	AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
Nov-02-23 04:15PM	Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +8.21%
Nov-01-23 09:15AM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-11-23 09:15AM	Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress (GlobeNewswire)
Oct-09-23 08:27AM	UPDATE 1-AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lizzul Paul F.	Chief Medical Officer	Jan 08 '26	Sale	44.71	3,650	163,192	42,088	Jan 09 07:16 PM
Paul F. Lizzul	Officer	Jan 08 '26	Proposed Sale	45.21	3,650	165,016		Jan 09 07:15 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 08 '26	Sale	44.71	2,515	112,446	21,852	Jan 09 07:14 PM
DENNIS MULROY	Officer	Jan 08 '26	Proposed Sale	45.21	2,515	113,703		Jan 09 07:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 08 '26	Sale	44.71	2,210	98,809	12,835	Jan 09 07:13 PM
ERIC J LOUMEAU	Officer	Jan 08 '26	Proposed Sale	45.21	2,210	99,914		Jan 09 07:12 PM
Faga Daniel	President, CEO	Jan 08 '26	Sale	44.71	14,281	638,504	479,344	Jan 09 07:12 PM
Daniel Faga	Officer	Jan 08 '26	Proposed Sale	45.21	14,281	645,644		Jan 09 07:11 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 07 '26	Sale	45.56	9,639	439,200	9,157	Jan 08 04:12 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	43.91	2,017	88,566		Jan 08 04:12 PM
Lizzul Paul F.	Chief Medical Officer	Jan 07 '26	Sale	45.11	2,235	100,821	37,213	Jan 08 04:11 PM
Paul F. Lizzul	Officer	Jan 07 '26	Proposed Sale	43.91	2,235	98,139		Jan 08 04:10 PM
Faga Daniel	President, CEO	Jan 07 '26	Sale	45.11	9,202	415,102	466,787	Jan 08 04:10 PM
Daniel Faga	Officer	Jan 07 '26	Proposed Sale	43.91	9,202	404,060		Jan 08 04:09 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 07 '26	Sale	45.11	1,908	86,070	17,667	Jan 08 04:08 PM
DENNIS MULROY	Officer	Jan 07 '26	Proposed Sale	43.91	1,908	83,780		Jan 08 04:08 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	45.69	7,622	348,213		Jan 07 04:06 PM
Faga Daniel	President, CEO	Jan 05 '26	Sale	43.26	15,309	662,267	458,139	Jan 06 09:07 PM
Daniel Faga	Officer	Jan 05 '26	Proposed Sale	44.95	15,309	688,140		Jan 06 09:07 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 05 '26	Sale	43.26	3,363	145,483	14,330	Jan 06 09:05 PM
DENNIS MULROY	Officer	Jan 05 '26	Proposed Sale	44.95	3,363	151,167		Jan 06 09:05 PM
Lizzul Paul F.	Chief Medical Officer	Jan 05 '26	Sale	43.26	4,219	182,514	33,303	Jan 06 09:04 PM
Paul F. Lizzul	Officer	Jan 05 '26	Proposed Sale	44.95	4,219	189,644		Jan 06 09:04 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 05 '26	Sale	43.26	2,983	129,045	13,251	Jan 06 09:03 PM
ERIC J LOUMEAU	Officer	Jan 05 '26	Proposed Sale	44.95	2,983	134,086		Jan 06 09:02 PM
Ware J. Anthony	Director	Dec 23 '25	Sale	49.58	3,900	193,342	9,630	Dec 23 04:30 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Option Exercise	18.50	1,500	27,750	28,467	Dec 23 04:28 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Sale	50.00	1,500	75,000	26,967	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	20.16	10,000	201,600	19,401	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Sale	50.00	10,000	500,000	9,401	Dec 23 04:28 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Option Exercise	14.02	10,000	140,200	18,947	Dec 23 04:27 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Sale	51.00	10,000	510,000	8,947	Dec 23 04:27 PM
JOE ANTHONY WARE	Director	Dec 23 '25	Proposed Sale	49.58	3,900	193,342		Dec 23 04:03 PM
ERIC J LOUMEAU	Officer	Dec 22 '25	Proposed Sale	51.00	10,000	510,000		Dec 22 04:05 PM
PAUL F LIZZUL	Officer	Dec 22 '25	Proposed Sale	50.00	1,500	75,000		Dec 22 04:04 PM
DENNIS MULROY	Officer	Dec 22 '25	Proposed Sale	50.00	10,000	500,000		Dec 22 04:01 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Option Exercise	17.70	12,500	221,300	21,588	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Option Exercise	14.02	10,000	140,200	19,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Sale	44.86	12,500	560,800	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Sale	46.00	10,000	460,000	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 18 '25	Sale	46.99	141	6,626	8,947	Dec 18 04:14 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Option Exercise	20.16	10,000	201,600	25,126	Dec 18 04:13 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Sale	44.85	15,725	705,333	9,401	Dec 18 04:13 PM
ERIC J LOUMEAU	Officer	Dec 18 '25	Proposed Sale	46.99	141	6,626		Dec 18 04:11 PM
ERIC J LOUMEAU	Officer	Dec 17 '25	Proposed Sale	46.00	10,000	460,000		Dec 17 04:12 PM
DENNIS MULROY	Officer	Dec 16 '25	Proposed Sale	44.85	15,725	705,333		Dec 16 04:58 PM
ERIC J LOUMEAU	Officer	Dec 16 '25	Proposed Sale	44.86	12,500	560,800		Dec 16 04:09 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Option Exercise	14.02	5,000	70,100	17,328	Oct 01 04:00 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Sale	29.00	8,240	238,960	9,088	Oct 01 04:00 PM
ERIC J LOUMEAU	Officer	Sep 30 '25	Proposed Sale	29.00	8,240	238,960		Sep 30 04:13 PM
Orwin John A	Director	Sep 15 '25	Option Exercise	0.00	1,300	0	10,665	Sep 17 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Option Exercise	6.93	10,231	70,901	15,196	Aug 12 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Sale	19.62	10,231	200,714	4,965	Aug 12 04:02 PM
HOLLINGS C RENTON	Director	Aug 08 '25	Proposed Sale	19.62	10,231	200,713		Aug 08 05:10 PM
RENTON HOLLINGS	Director	Jul 02 '25	Option Exercise	6.93	20,925	145,010	25,890	Jul 03 01:34 PM
RENTON HOLLINGS	Director	Jul 02 '25	Sale	23.57	20,925	493,191	4,965	Jul 03 01:34 PM
HOLLINGS C RENTON	Director	Jul 02 '25	Proposed Sale	23.57	20,925	493,190		Jul 02 04:13 PM
FENTON DENNIS M	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:07 PM
RENTON HOLLINGS	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:06 PM
HOLLINGS C RENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:26 PM
DENNIS M FENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:06 PM
Jain Rita	Director	Jun 15 '25	Option Exercise	0.00	7,330	0	11,864	Jun 17 06:33 PM
FENTON DENNIS M	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:33 PM
Marquet Magda	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,930	Jun 17 06:32 PM
Orwin John A	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,365	Jun 17 06:31 PM
RENTON HOLLINGS	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:30 PM
Schmid John P.	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	52,267	Jun 17 06:30 PM
Ware J. Anthony	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	13,530	Jun 17 06:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANAB

AnaptysBio Inc

Upgrade your FINVIZ experience